0001104659-23-040537 8-K 14 20230403 2.02 9.01 20230403 20230403 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 8-K 34 001-39202 23790659 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 8-K 1 tm2311180d1_8k.htm FORM 8-K
0001477845 false 0001477845 2023-04-03 2023-04-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares















Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): April 3, 2023





(Exact Name of Registrant as Specified in Charter) 


Delaware 001-39202 26-2540421

(State or Other Jurisdiction

of Incorporation)


File Number)

(I.R.S. Employer

Identification No.)


1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

(Address of Principal Executive Offices, and Zip Code)


(610) 727-3913

Registrant’s Telephone Number, Including Area Code


                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which
Common Stock, par value $0.0001 per share ANVS New York Stock Exchange




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x







Item 2.02 Results of Operations and Financial Condition.


On April 3, 2023, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2022 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.


The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.  


99.1   Press Release, dated April 3, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: April 3, 2023 By: /s/ Henry Hagopian III  
    Name: Henry Hagopian III
    Title: Chief Financial Officer




EX-99.1 2 tm2311180d1_ex99-1.htm EXHIBIT 99.1


Exhibit 99.1 




BERWYN, Penn., April 3, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, has announced fourth quarter and full year financial results for the period ended December 31, 2022, and reviewed recent accomplishments.




Fourth Quarter Highlights and New Developments


·Received approval for European Union clinical trial sites for the Phase 3 study of buntanetap for the treatment of early Parkinson's disease: On February 8, 2023, the Company announced the approval for additional European clinical trial sites for the ongoing Phase 3 study of buntanetap for the treatment of Parkinson's disease ("PD"). Annovis is actively recruiting for the ongoing Phase 3 study with approximately 53 clinical trial sites open and currently enrolling in the United States. The approval adds an additional approximately 49 sites in the EU for the Company's Phase 3 study of buntanetap for the treatment of Early PD.


·Announced filing of patent application covering the administration of buntanetap and its analogues for the treatment of mental illnesses: On February 1, 2023, the Company announced the filing of a provisional patent application that extends the breadth of its platform from neurodegenerative to neuropsychiatric indications: "Treatment of mental illness via administration of buntanetap and analogues."


·Announced new appointments to strengthen its senior leadership team: On January 6, 2023, the Company announced the appointment Michael Christie, Ph.D. as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology. Dr. Christie has over 40 years of experience in the pharmaceutical industry and formally served as the Senior Director of Chemical Process and R&D for Teva Pharmaceuticals. Mr. Prohaska brings 25 years of experience in all aspects of preclinical drug development and has a long track record of successful FDA submissions with multiple drug approvals. Mr. Prohaska joined Annovis from Aravive Biologics where he served as the Director of Preclinical Development and Clinical Operations Support.





·Publication of Phase 1/2 clinical data in The Journal of Prevention of Alzheimer's Disease: On October 11, 2022, the Company announced the publication of a study, titled 'Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients', evaluated safety, pharmacokinetics, biomarkers, and efficacy of buntanetap in treating early AD and PD patients. Buntanetap was observed to be well tolerated and significantly improved cognition in AD patients and motor function in PD patients.

·Receipt of FDA authorization to proceed with Phase 2/3 trial for buntanetap in mild to moderate Alzheimer's disease (AD)On October 6, 2022, the Company announced that the FDA authorized the Phase 2/3 clinical study of buntanetap in mild to moderate AD. The Phase 2/3 study is a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap in mild to moderate AD patients. The trial will enroll a total of 320 mild to moderate AD patients to be treated with 7.5, 15 or 30mg of buntanetap or placebo, in addition to any drugs they regularly take, for three months.


·Interim analysis for Phase 3 study of buntanetap for the treatment of early Parkinson's disease (PD): On March 31, 2023, the Company announced that it had received the results of the pre-planned blinded interim analysis conducted by a data analytics provider based on 132 patients from all cohorts collectively for which baseline and two-month data was available. As the interim analysis was conducted at two months of the six-month endpoint and only on 132 patients, it may not be indicative of the results at six months for the full patient population because as the trial progresses, clinical outcomes may materially change as patient enrollment continues and more patient data become available, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Based on the results of the interim analysis, the Company intends to proceed with the trial as planned in accordance with the previously established protocol.

Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented: “The fourth quarter and subsequent announcements in early 2023 highlight continued execution and productivity across many facets of our business. We are pleased with the pace of enrollment in our ongoing clinical trials. We expect to report a blinded interim analysis of our Phase 2/3 Alzheimer’s study in Fall 2023. We are also building an expansive intellectual property estate surrounding the use of buntanetap and its analogues across a myriad of neuro-inflammatory diseases and conditions. As our clinical activities continue to expand, we are also managing this growth through the appointments of key senior-level professionals who will play a pivotal role as we reach key inflection points in our clinical programs. We believe 2023 promises to be an exciting year for Annovis driven by our team’s continued execution, and the strong therapeutic potential of our lead drug candidate, buntanetap, to address the unmet medical need in Alzheimer’s and Parkinson’s disease.”





Financial Results for the Fourth Quarter of 2022

Cash and cash equivalents were $28.4 million as of December 31, 2022. Research and development expenses for the quarter ended December 31, 2022 were $6.2 million, compared to $2.9 million for the same period in 2021. The increase was primarily the result of an increase of $4.3 million in clinical expenses, as the Company incurred costs related to its Phase 3 study in early PD patients and its Phase 2/3 Alzheimer’s study, partially offset by a decrease of $1.0 million in stock-based compensation expense. General and administrative expenses for the quarter ended December 31, 2022 were $1.6 million, compared to $3.0 million for the same period in 2021. The decrease was primarily the result of a decrease of $1.5 million in stock-based compensation expense.


For the quarter ended December 31, 2022, Annovis reported a net loss of $7.7 million, compared to a net loss of $5.9 million for the same period in 2021.


Financial Results for the Full Year 2022

Research and development expenses for the year ended December 31, 2022, were $16.5 million, compared to $8.5 million for the same period in 2021. The increase was primarily the result of an increase of $6.6 million in clinical expenses, as the Company incurred costs related to its Phase 3 study in early PD patients, its Phase 2/3 Alzheimer’s study and an increase of $1.4 million in stock-based compensation expense. General and administrative expenses for the year ended December 31, 2022 were $9.0 million, compared to $6.1 million for the same period in 2021. The increase was primarily the result of an increase of $3.1 million in stock-based compensation expense.





For the full year ended 2022, Annovis reported a net loss of $25.3 million, compared to a net loss of $14.5 million in 2021.


About Buntanetap

Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. In a Phase 1/2 clinical trial in Alzheimer's disease (AD) and Parkinson's disease (PD) patients, buntanetap was shown to be well-tolerated and its pharmacokinetics were found to be in line with levels measured earlier in humans, meeting both the primary and secondary endpoints. Additionally, exploratory endpoints were also met, as treatment with buntanetap resulted in statistically significant improvement in motor function in PD patients and cognition in AD patients. Presently buntanetap is being studied in a Phase 3 study in early PD patients and in a Phase 2/3 study in mild to moderate AD patients.


About Annovis Bio, Inc.

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD), and other chronic neurodegenerative diseases. We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein, and has a mechanism of action designed to restore nerve cell axonal and synaptic activity.. By improving brain function, our goal is to treat memory loss and dementia associated with AD as well as body and brain function associated with PD. Annovis conducted two Phase 1/2 studies: one in AD patients and one in both AD and PD patients. In the AD/PD study buntanetap showed improvements in cognition in AD as well as body and function in PD patients.


For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter.


Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company’s plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding, patient enrollment, the effectiveness of Buntanetap and the timing, effectiveness, and anticipated results of the Company’s clinical trials evaluating the efficacy, safety and tolerability of Buntanetap. See also additional risk factors set forth in the Company’s periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.








EX-101.SCH 3 anvs-20230403.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 anvs-20230403_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 anvs-20230403_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2311180d1_ex99-1img001.jpg GRAPHIC begin 644 tm2311180d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Apr. 03, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 03, 2023
Entity File Number 001-39202
Entity Registrant Name ANNOVIS BIO, INC.
Entity Central Index Key 0001477845
Entity Tax Identification Number 26-2540421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1055 Westlakes Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Berwyn
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19312
City Area Code 610
Local Phone Number 727-3913
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ANVS
Security Exchange Name NYSE
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 8 tm2311180d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001477845 2023-04-03 2023-04-03 iso4217:USD shares iso4217:USD shares 0001477845 false 8-K 2023-04-03 ANNOVIS BIO, INC. DE 001-39202 26-2540421 1055 Westlakes Drive Suite 300 Berwyn PA 19312 610 727-3913 Common Stock, par value $0.0001 per share ANVS NYSE false false false false true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://annovisbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2311180d1_8k.htm anvs-20230403.xsd anvs-20230403_lab.xml anvs-20230403_pre.xml tm2311180d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2311180d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2311180d1_8k.htm" ] }, "labelLink": { "local": [ "anvs-20230403_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20230403_pre.xml" ] }, "schema": { "local": [ "anvs-20230403.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ANVS", "nsuri": "http://annovisbio.com/20230403", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2311180d1_8k.htm", "contextRef": "From2023-04-03to2023-04-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://annovisbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2311180d1_8k.htm", "contextRef": "From2023-04-03to2023-04-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-040537-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-040537-xbrl.zip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end